Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy

Am J Hematol. 2021 Oct 1;96(10):E362-E367. doi: 10.1002/ajh.26273. Epub 2021 Jul 2.

Authors

Antoine N Saliba^{1

2}, Zhuoer Xie^{1

2}, Alexandra S Higgins^{1

2}, Xavier A Andrade-Gonzalez^{1

2}, Harry E Fuentes-Bayne^{1

2}, Paul J Hampel^{1

2}, Lionel A Kankeu Fonkoua^{1

2}, Daniel S Childs^{1

2}, Sagar Rakshit^{1

2}, Evandro D Bezerra^{1

2}, Anuhya Kommalapati^{1

2}, Yanyan Lou³, Candido E Rivera³, Katharine A Price², Ashish Chintakuntlawar², Yiyi Yan², Anna J Schwecke², Matthew S Block², Uma Thanarajasingam⁴, Gita Thanarajasingam¹, Alexandra P Wolanskyj-Spinner¹, Ariela L Marshall^{1

5}, Lisa A Kottschade², Ronald S Go¹, Aref Al-Kali¹

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
² Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
³ Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
⁴ Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
⁵ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 34137072
DOI: 10.1002/ajh.26273

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Female
Hematologic Diseases / blood
Hematologic Diseases / chemically induced*
Humans
Immune Checkpoint Inhibitors / adverse effects*
Immunotherapy / adverse effects
Male
Middle Aged

Substances

Immune Checkpoint Inhibitors